Assessment effect of Galega on sugar level of diabetic 2 patients

Formulations of 500 mg of Galega tablets and its examination on the reduction of blood glucose in diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190521043652N1

Enrollment

Registered

2019-07-16

Start date

2019-07-11

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: the treatment group will take Galega 500 mg tablets twice a day for three months, in addition to routine treatment of diabetes. Intervention 2: Control group: the c

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Having type 2 diabetes The questionnaire completion

Exclusion criteria

Exclusion criteria: Incomplete questionnaire

Design outcomes

Primary

Measure	Time frame
The blood glucose. Timepoint: Monthly for three months and fasting and two hours after meals. Method of measurement: By laboratory kit.;Hemoglobin A1c. Timepoint: In the third month after the start of the study. Method of measurement: By laboratory kit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactYousef Javadzadeh

Tabriz University of Medical Sciences

javadzadehy@yahoo.com+98 41 3337 2250

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026